Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High – Should You Buy?

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) hit a new 52-week high during trading on Monday . The company traded as high as $27.98 and last traded at $27.98, with a volume of 450 shares traded. The stock had previously closed at $27.44.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $33.60.

Kiniksa Pharmaceuticals Price Performance

The company has a market cap of $1.66 billion, a price-to-earnings ratio of -145.41 and a beta of 0.33. The firm’s 50 day simple moving average is $25.64 and its 200-day simple moving average is $22.42.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, COO Eben Tessari sold 17,500 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 112,692 shares of company stock worth $2,950,315 over the last 90 days. Corporate insiders own 54.57% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several hedge funds have recently made changes to their positions in KNSA. Hhlr Advisors LTD. acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $61,868,000. Millennium Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after buying an additional 382,539 shares during the period. Rubric Capital Management LP boosted its stake in shares of Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after buying an additional 223,094 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares during the period. Finally, Hussman Strategic Advisors Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $3,107,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.